Rapport Therapeutics, Inc. Common Stock (RAPP) - Stock Analysis
Last updated: Sep 19, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Persistent Cash Burn ⢠No Revenue RAPP's strong liquidity and low leverage are outweighed by no revenue, substantial losses, persistent cash burn, and a valuation premium reliant on its shrinking investment base.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support test ⢠Oversold momentum Support Level: $40.00â$40.50 Resistance Level: $43.50â$44.00; $46.00â$48.00 RAPP remains bearish after a 16% last-month decline, though deeply oversold momentum may support a short-term rebound if $40.00â$40.50 holds.
Sentiment & News
Key News Insights: ⢠Institutional accumulation ⢠RAP-219 catalyst ⢠Funding risk Rapport Therapeutics hit a 12-month high amid strong institutional buying and investor engagement, though RAP-219's regulatory and funding risks remain key watchpoints.
AI Summary
RAPP has shifted from a funding-risk biotech to a well-capitalized, high-expectations bet on RAP-219, making October bipolar-mania data and Phase 3 epilepsy execution decisive catalysts; investors should view the oversold pullback as tactical only until pivotal efficacy and long-exposure safety validate the premium valuation.
Description
Rapport Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for central nervous system disorders. Its lead candidate, RAP-219, is a high-affinity inhibitor of TARPy8-containing AMPA receptors being evaluated for focal epilepsy and other CNS indications; the pipeline also includes an additional TARPy8 program and nicotinic acetylcholine receptor projects targeting chronic pain and hearing disorders. The company was incorporated in 2022, renamed from Precision Neuroscience NewCo in October 2022, and is based in Boston, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 15 | Sep 22 | RAPP | Rapport Therapeutics, Inc. Common Stock | Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term. | Closed | +5.6% |